0.5988
price down icon3.48%   -0.0216
after-market アフターアワーズ: .59 -0.0088 -1.47%
loading
前日終値:
$0.6204
開ける:
$0.61
24時間の取引高:
2.40M
Relative Volume:
1.35
時価総額:
$47.96M
収益:
$101.21M
当期純損益:
$-569.00K
株価収益率:
-29.94
EPS:
-0.02
ネットキャッシュフロー:
$-56.88M
1週間 パフォーマンス:
-2.67%
1か月 パフォーマンス:
-24.63%
6か月 パフォーマンス:
-52.10%
1年 パフォーマンス:
-72.15%
1日の値動き範囲:
Value
$0.57
$0.624
1週間の範囲:
Value
$0.57
$0.777
52週間の値動き範囲:
Value
$0.57
$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
名前
Cytomx Therapeutics Inc
Name
セクター
Healthcare (1172)
Name
電話
650.515.3185
Name
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
職員
121
Name
Twitter
@cytomxinc
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
CTMX's Discussions on Twitter

CTMX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CTMX
Cytomx Therapeutics Inc
0.5988 47.96M 101.21M -569.00K -56.88M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
495.42 127.22B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
689.50 75.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.45 35.94B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.43 31.38B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.84 26.84B 3.32B -860.46M -1.04B -8.32

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-05-28 アップグレード Piper Sandler Neutral → Overweight
2024-05-09 アップグレード Wedbush Neutral → Outperform
2024-05-06 アップグレード Jefferies Hold → Buy
2024-04-22 アップグレード JP Morgan Underweight → Neutral
2022-11-14 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-07-07 ダウングレード Jefferies Buy → Hold
2022-07-07 ダウングレード Mizuho Buy → Neutral
2022-07-07 ダウングレード Piper Sandler Overweight → Neutral
2022-07-07 ダウングレード Wedbush Outperform → Neutral
2022-06-24 開始されました BMO Capital Markets Outperform
2022-01-18 アップグレード Barclays Underweight → Overweight
2021-11-15 開始されました BTIG Research Buy
2021-05-28 ダウングレード Barclays Equal Weight → Underweight
2021-03-29 開始されました JP Morgan Overweight
2021-03-23 アップグレード Jefferies Hold → Buy
2020-09-22 ダウングレード Guggenheim Buy → Neutral
2020-06-01 ダウングレード Jefferies Buy → Hold
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-03-24 アップグレード Wedbush Neutral → Outperform
2020-03-04 開始されました Barclays Equal Weight
2019-11-20 開始されました Guggenheim Buy
2019-11-11 ダウングレード Wedbush Outperform → Neutral
2019-06-13 開始されました Mizuho Buy
2019-05-14 開始されました Cantor Fitzgerald Overweight
2019-03-11 開始されました Barclays Overweight
2018-11-26 開始されました Piper Jaffray Overweight
2018-10-15 開始されました Goldman Neutral
2018-09-13 開始されました H.C. Wainwright Buy
2018-06-01 開始されました SunTrust Buy
2018-01-05 開始されました Citigroup Buy
2017-09-08 開始されました Wedbush Outperform
2017-03-27 開始されました H.C. Wainwright Buy
2017-03-02 開始されました Instinet Buy
2017-01-03 ダウングレード Oppenheimer Outperform → Perform
2015-11-02 開始されました Oppenheimer Outperform
すべてを表示

Cytomx Therapeutics Inc (CTMX) 最新ニュース

pulisher
Mar 12, 2025

CytomX at Barclays Healthcare: Probody Platform Progress - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India

Mar 12, 2025
pulisher
Mar 11, 2025

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Mar 11, 2025
pulisher
Mar 11, 2025

Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News

Mar 11, 2025
pulisher
Mar 11, 2025

CytomX Therapeutics (NASDAQ:CTMX) Upgraded by StockNews.com to “Buy” Rating - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

What Are You Thinking About Investing In CytomX Therapeutics Inc (NASDAQ: CTMX) Stock? - Stocks Register

Mar 10, 2025
pulisher
Mar 10, 2025

CytomX Therapeutics’ (CTMX) Outperform Rating Reiterated at Wedbush - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Brokerages - Armenian Reporter

Mar 10, 2025
pulisher
Mar 10, 2025

CytomX Therapeutics’ (CTMX) “Neutral” Rating Reiterated at HC Wainwright - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025
pulisher
Mar 08, 2025

CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 08, 2025
pulisher
Mar 08, 2025

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - TipRanks

Mar 08, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now - Insider Monkey

Mar 07, 2025
pulisher
Mar 07, 2025

Deal Watch: Amgen, CytomX Pull Back On Part Of T-Cell Engager Collaboration - Citeline News & Insights

Mar 07, 2025
pulisher
Mar 07, 2025

Cautious Outlook for CytomX Therapeutics Amid Pipeline Challenges and Strategic Setbacks - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX stock plunges to 52-week low, touches $0.6 By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Insights - GuruFocus.com

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics Inc earnings beat by $0.43, revenue topped estimates - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Mar 07, 2025
pulisher
Mar 06, 2025

CytomX Therapeutics Reports Strong 2024 Financial Results - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

CytomX To Report Colorectal Cancer Trial Data Of CX-2051 In 1H, 2025 - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

CytomX Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue By Investing.com - Investing.com UK

Mar 06, 2025
pulisher
Mar 06, 2025

CYTOMX THERAPEUTICS Earnings Results: $CTMX Reports Quarterly Earnings - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

CytomX Therapeutics Inc Reports Q4 EPS of $0.38 and Revenue of $138.1 Million, Surpassing Estimates - GuruFocus.com

Mar 06, 2025
pulisher
Mar 06, 2025

CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

CytomX Therapeutics Advances CX-2051 and CX-801 Programs, Reports Strengthened Financial Position - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

CytomX stock plunges to 52-week low, touches $0.6 - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Daily Progress: CytomX Therapeutics Inc (CTMX) Drop -5.76, Closing at 0.62 - The Dwinnex

Mar 06, 2025
pulisher
Mar 06, 2025

10 Cheap Growth Stocks to Buy Now - Insider Monkey

Mar 06, 2025
pulisher
Mar 06, 2025

CytomX Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 05, 2025

CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect? - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference - The Manila Times

Mar 05, 2025
pulisher
Mar 05, 2025

Can CytomX's Conference Presentation Reveal New Strategic Directions for Its Masked Biologics Platform? - StockTitan

Mar 05, 2025
pulisher
Mar 05, 2025

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q4 202 - GuruFocus.com

Mar 05, 2025
pulisher
Mar 05, 2025

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q4 2024 Result - Yahoo Finance

Mar 05, 2025
pulisher
Mar 04, 2025

CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Mar 04, 2025
pulisher
Mar 01, 2025

CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

CytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Below Fifty Day Moving AverageShould You Sell? - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - The Manila Times

Feb 27, 2025
pulisher
Feb 27, 2025

When Will CytomX Release Q4 2024 Results? Key Date for Biotech Investors - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

CytomX faces Nasdaq delisting over share price woes - Investing.com India

Feb 27, 2025
pulisher
Feb 26, 2025

CytomX faces Nasdaq delisting over share price woes By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 24, 2025

CytomX stock hits 52-week low at $0.74 amid market challenges - Investing.com Nigeria

Feb 24, 2025
pulisher
Feb 24, 2025

CytomX stock hits 52-week low at $0.74 amid market challenges By Investing.com - Investing.com South Africa

Feb 24, 2025

Cytomx Therapeutics Inc (CTMX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$35.01
price up icon 3.70%
$307.09
price up icon 0.88%
$32.85
price up icon 1.20%
$19.91
price up icon 7.62%
$100.31
price up icon 1.95%
biotechnology ONC
$249.84
price up icon 1.68%
大文字化:     |  ボリューム (24 時間):